Viking Therapeutics initiates Phase 3 clinical trials for oral VK2735
VKTX Viking Therapeutics Inc
$25.05 -0.48%
View chart & analysis → - 1Viking Therapeutics recently initiated SUNRISE-1 and SUNRISE-2, Phase 3 clinical trials for oral VK2735 targeting patients with obesity and type 2 diabetes.
- 2A 20% discontinuation rate due to adverse events was previously recorded among participants in the VENTURE-Oral trial during the 13-week VENTURE-Oral study.
- 3Viking Therapeutics has a market capitalization of $3.19 billion.
So what's the key point?
Viking Therapeutics has started the final stage of testing for its oral medication. In a previous study, 20% of participants stopped taking the drug due to side effects.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.